Parnell Pharmaceuticals Holdings Long Term Debt 2014-2018 | PARNF
Parnell Pharmaceuticals Holdings long term debt from 2014 to 2018. Long term debt can be defined as the sum of all long term debt fields.
Parnell Pharmaceuticals Holdings Annual Long Term Debt
(Millions of US $) |
| 2021 |
$44 |
| 2020 |
$38 |
| 2019 |
$30 |
| 2018 |
$34 |
| 2017 |
$25 |
| 2016 |
$22 |
| 2015 |
$11 |
| 2014 |
$1 |
| 2014 |
$0 |
| 2013 |
$0 |
| 2013 |
$0 |
| 2012 |
$0 |
Parnell Pharmaceuticals Holdings Quarterly Long Term Debt
(Millions of US $) |
| 2018-03-31 |
$26 |
| 2017-12-31 |
$25 |
| 2016-12-31 |
$22 |
| 2016-09-30 |
$8 |
| 2015-12-31 |
$11 |
| 2015-09-30 |
|
| 2015-06-30 |
$11 |
| 2015-03-31 |
|
| 2014-12-31 |
$1 |
| 2014-09-30 |
|
| 2014-06-30 |
$0 |
| 2014-03-31 |
$24 |
| 2013-06-30 |
$4 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.000B |
$0.000B |
|
Parnell Pharmaceuticals Holdings Ltd. is a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing animal health solutions. It manufactures and markets cattle reproduction, cattle mastitis, anesthetics, laminitis treatment, and orthopedic treatment products. The Company operates in four segments: Companion Animal, Production Animal-Unites States, and Production Animal-rest of the world and Manufacturing Operations. ZYDAX (R), GLYDE (R) and TERGIVE (R) are Parnell's premium osteoarthritis product suite. Parnell Pharmaceuticals Holdings Ltd. is headquartered in Alexandria, Australia.
|
